Free tool
FAERS Monitor: Bilprevda
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761444 or its brand name (Bilprevda, Denosumab-Nxxp). Reports on generic versions are filed under their own applications.
Reports
16,625
Serious
15,968
96% of reports
Hospitalization
6,867
Death reported
1,943
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- osteonecrosis of jaw1,555
- diarrhoea1,177
- fatigue1,139
- nausea1,088
- malignant neoplasm progression1,072
- neutropenia981
- metastases to bone857
- off label use847
- anaemia758
- vomiting619
- dyspnoea609
- hypocalcaemia608
- decreased appetite606
- drug ineffective554
- pyrexia535
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2008 | 1 |
| 2009 | 2 |
| 2010 | 67 |
| 2011 | 136 |
| 2012 | 214 |
| 2013 | 358 |
| 2014 | 474 |
| 2015 | 662 |
| 2016 | 748 |
| 2017 | 636 |
| 2018 | 956 |
| 2019 | 1,013 |
| 2020 | 1,063 |
| 2021 | 1,495 |
| 2022 | 1,772 |
| 2023 | 1,781 |
| 2024 | 1,728 |
| 2025 | 1,749 |
| 2026 | 1,770 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,037,534 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| osteonecrosis of jawSignal | 1,555 | 84.8 | 80.7 | 120,690 |
| metastases to boneSignal | 857 | 69.6 | 65.1 | 54,931 |
| hypocalcaemiaSignal | 608 | 42.0 | 38.8 | 23,507 |
| malignant neoplasm progressionSignal | 1,072 | 13.4 | 12.6 | 12,190 |
| neutropeniaSignal | 981 | 9.2 | 8.6 | 7,144 |
| anaemiaSignal | 758 | 5.0 | 4.7 | 2,466 |
| decreased appetiteSignal | 606 | 3.3 | 3.1 | 981 |
| diarrhoeaSignal | 1,177 | 2.3 | 2.2 | 898 |
| pyrexia | 535 | 2.0 | 1.8 | 253 |
| fatigue | 1,139 | 1.9 | 1.8 | 462 |
| nausea | 1,088 | 1.7 | 1.6 | 355 |
| vomiting | 619 | 1.7 | 1.5 | 168 |
| dyspnoea | 609 | 1.4 | 1.3 | 60 |
| off label use | 847 | 1.2 | 1.1 | 36 |
| drug ineffective | 554 | 0.5 | 0.5 | 243 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.